Robert S Rosenson

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi Management of non-high-density lipoprotein abnormalities
    Robert S Rosenson
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA
    Atherosclerosis 207:328-35. 2009
  2. ncbi Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus
    Robert S Rosenson
    Cardiometabolic Disorders, Mt Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, MC1 Level, New York, NY, 10029, USA
    Cardiovasc Drugs Ther 28:229-36. 2014
  3. ncbi An assessment by the Statin Muscle Safety Task Force: 2014 update
    Robert S Rosenson
    Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA Electronic address
    J Clin Lipidol 8:S58-71. 2014
  4. pmc Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values
    Robert S Rosenson
    Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
    Cardiovasc Drugs Ther 27:465-79. 2013
  5. doi Phospholipase A2 enzymes and the risk of atherosclerosis
    Robert S Rosenson
    Mount Sinai School of Medicine, 1425 Madison Ave, Box 1030, New York, NY 10029, USA
    Eur Heart J 33:2899-909. 2012
  6. doi Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
    Robert S Rosenson
    Department of Cardiometabolic Disorders, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am Heart J 164:672-80. 2012
  7. pmc Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2
    Robert S Rosenson
    Mount Sinai School of Medicine, New York, NY 10029, USA
    J Lipid Res 53:1767-82. 2012
  8. doi HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events
    Robert S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY, USA
    Clin Chem 57:392-410. 2011
  9. doi Does microvascular disease predict macrovascular events in type 2 diabetes?
    R S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
    Atherosclerosis 218:13-8. 2011
  10. doi Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome
    Robert S Rosenson
    Mount Sinai School of Medicine, NY 10029, USA
    Cardiovasc Drugs Ther 25:539-44. 2011

Detail Information

Publications23

  1. ncbi Management of non-high-density lipoprotein abnormalities
    Robert S Rosenson
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA
    Atherosclerosis 207:328-35. 2009
    ..Improvement in lipid control and reduction in atherogenic risk could be anticipated to translate to benefits in clinical outcomes...
  2. ncbi Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus
    Robert S Rosenson
    Cardiometabolic Disorders, Mt Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, MC1 Level, New York, NY, 10029, USA
    Cardiovasc Drugs Ther 28:229-36. 2014
    ..5 to ≤9.5 %) with diet and exercise alone; we report here the effects on lipoprotein particle subclasses...
  3. ncbi An assessment by the Statin Muscle Safety Task Force: 2014 update
    Robert S Rosenson
    Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA Electronic address
    J Clin Lipidol 8:S58-71. 2014
    ..The panel was composed of clinical cardiologists, clinical lipidologists, an exercise physiologist, and a neuromuscular specialist. ..
  4. pmc Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values
    Robert S Rosenson
    Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
    Cardiovasc Drugs Ther 27:465-79. 2013
    ..This systematic review was performed to summarize published experience using low density lipoprotein particle number (LDL-P) to monitor the efficacy of lipid-lowering pharmacotherapies...
  5. doi Phospholipase A2 enzymes and the risk of atherosclerosis
    Robert S Rosenson
    Mount Sinai School of Medicine, 1425 Madison Ave, Box 1030, New York, NY 10029, USA
    Eur Heart J 33:2899-909. 2012
    ..This article reviews the available experimental animal and human trial evidence that serve as the basis for the development of these two classes of phospholipase A(2) inhibitors...
  6. doi Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
    Robert S Rosenson
    Department of Cardiometabolic Disorders, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am Heart J 164:672-80. 2012
    ....
  7. pmc Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2
    Robert S Rosenson
    Mount Sinai School of Medicine, New York, NY 10029, USA
    J Lipid Res 53:1767-82. 2012
    ....
  8. doi HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events
    Robert S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY, USA
    Clin Chem 57:392-410. 2011
    ....
  9. doi Does microvascular disease predict macrovascular events in type 2 diabetes?
    R S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
    Atherosclerosis 218:13-8. 2011
    ..The aim of this review was to investigate whether this association extended to the presence of any diabetic microvascular complication...
  10. doi Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome
    Robert S Rosenson
    Mount Sinai School of Medicine, NY 10029, USA
    Cardiovasc Drugs Ther 25:539-44. 2011
    ..This study evaluated baseline differences in sPLA(2)-IIA concentration and other inflammatory markers in ACS patients with and without diabetes, and the inflammatory biomarker response to selective sPLA(2) inhibition...
  11. pmc Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus
    Robert S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Cardiovasc Drugs Ther 25:47-57. 2011
    ....
  12. doi Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease
    Robert S Rosenson
    Mount Sinai Heart Box 1030, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Eur Heart J 32:999-1005. 2011
    ..Secretory phospholipase A2 isoenzymes promote atherosclerosis by mechanisms that include lipoprotein modification, retention, and oxidation...
  13. doi Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy
    Robert S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1070, New York, NY 10017, USA
    Cardiovasc Drugs Ther 24:439-47. 2010
    ..We investigate the effects of fenofibrate therapy on postprandial triglyceride-containing lipoproteins in subjects with early (3.5 h) versus late (8 h) postprandial triglyceride responses...
  14. doi Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients
    Robert S Rosenson
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Coll Cardiol 56:1079-88. 2010
    ..The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary syndrome patients...
  15. ncbi Varespladib methyl in cardiovascular disease
    Robert S Rosenson
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Expert Opin Investig Drugs 19:1245-55. 2010
    ..Analyses of clinical trials in statin-treated patients demonstrate that elevated lipid levels and an activated systemic inflammatory state are associated with a higher risk of recurrent cardiovascular events...
  16. doi Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes
    Robert S Rosenson
    Mount Sinai School of Medicine, New York, New York, USA
    Curr Opin Lipidol 21:473-80. 2010
    ....
  17. doi Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk
    Robert S Rosenson
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Atherosclerosis 213:1-7. 2010
    ....
  18. doi New technologies personalize diagnostics and therapeutics
    Robert S Rosenson
    Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029 6574, USA
    Curr Atheroscler Rep 12:184-6. 2010
    ..The application of genomics, proteomics, and metabolomics provides opportunities to improve our understanding of the complex process of atherosclerosis and enables personalized diagnostic and therapeutic approaches...
  19. doi After FRANCIS: next steps in the clinical evaluation of varespladib methyl
    Robert S Rosenson
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Future Cardiol 7:11-8. 2011
    ....
  20. ncbi Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome
    Robert S Rosenson
    From the Department of Medicine Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY R S R Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, DC H B B and Departments of Medicine and Genetics and Cardiovascular Institute, Perelman School of Medicine of the University of Pennsylvania, Philadelphia D J R
    Circ Res 114:1880-9. 2014
    ..Here, we review the relationship of lipoproteins as biomarkers to cardiovascular risk after ACS, the evidence for lipid-targeted interventions, and the potential for novel therapeutic approaches in this arena. ..
  21. doi Emerging drugs for hyperlipidemia
    Christos Paras
    SUNY Downstate Medical Center, Brooklyn, NY, USA
    Expert Opin Emerg Drugs 15:433-51. 2010
    ..The mainstays of lipid lowering therapy today are the HMG-CoA reductase inhibitors (statins); however, the residual risk of cardiovascular events amongst individuals treated with statins remains a major healthcare concern...
  22. doi Importance of blood rheology in the pathophysiology of atherothrombosis
    Aimee Q Cowan
    Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cardiovasc Drugs Ther 26:339-48. 2012
    ....
  23. doi Recombinant high-density lipoprotein formulations
    Esad Vucic
    Translational and Molecular Imaging Institute, Imaging Science Laboratories, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Curr Atheroscler Rep 13:81-7. 2011
    ..This review presents our current knowledge on novel recombinant therapies, and their future prospects to mitigate atherosclerotic CVD events...